Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR versus octreotide LAR in metastatic carcinoid tumors with inadequately controlled carcinoid syndrome symptoms
NL-OMON35353Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Tumor (CT) and Carcinoid Syndrome (CS) comparing Pasireotide LAR with Octreotide LAR active control (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Mar 2009; status: withdrawn.
02
Drugs
pasireotide LARoctreotide
03
Conditions
Carcinoid Tumor (CT)Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NL-OMON35353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35353.